Evidence map›Paper›PMID 36626549›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2023

OGT controls mammalian cell viability by regulating the proteasome/mTOR/ mitochondrial axis.

Xiang Li, Xiaojing Yue, Hugo Sepulveda, Rajan A Burt, David A Scott, Steven A Carr, Samuel A Myers, Anjana Rao

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Perturbing nuclear glycosylation in the mouse preimplantation embryo slows down embryonic development.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Dissecting OGT's TPR domain to identify determinants of cellular function.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Xiang LiDivision of Signaling and Gene Expression, La Jolla Institute for Immunology, La Jolla, CA 92037.ORCID 0000-0001-8723-4771
Xiaojing YueDivision of Signaling and Gene Expression, La Jolla Institute for Immunology, La Jolla, CA 92037.
Hugo SepulvedaDivision of Signaling and Gene Expression, La Jolla Institute for Immunology, La Jolla, CA 92037.
Rajan A BurtThe Broad Institute of MIT and Harvard, Cambridge, MA 02142.
David A ScottCancer Metabolism Core, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037.
Steven A CarrThe Broad Institute of MIT and Harvard, Cambridge, MA 02142.
Samuel A MyersDivision of Signaling and Gene Expression, La Jolla Institute for Immunology, La Jolla, CA 92037.
Anjana RaoDivision of Signaling and Gene Expression, La Jolla Institute for Immunology, La Jolla, CA 92037.ORCID 0000-0002-1870-1775
La Jolla Institute for Immunology · USBroad Institute · USSanford Burnham Prebys Medical Discovery Institute · US

Funding

Tumor Microenvironment and Cancer ImmunologyP30CA030199 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ELENA B PASQUALE · 1985 to 2026
$107.2M
The TET-DNMT-ASXL1-OGT axis: relevance to clonal hematopoiesis, heterochromatin integrity and cancerR35CA210043 · NCI · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI Anjana Rao · 2016 to 2026
$10.6M
Center of Excellence for High Throughput Proteogenomic CharacterizationU24CA270823 · NCI · BROAD INSTITUTE, INC. · PI STEVEN A CARR, MICHAEL A GILLETTE · 2022 to 2026
$5.3M
Exploring the potential of TET inhibition in cancer immunotherapyR01CA247500 · NCI · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI RAO, ANJANA · 2020 to 2024
$2.7M
Illumina HiSeq 2500 Sequencing SystemS10OD016262 · OD · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI RAO, ANJANA · 2013 to 2013
$600k
FACSAria II Cell SorterS10RR027366 · NCRR · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI CROFT, MICHAEL · 2011 to 2011
$514k
NCI NIH HHS P30 CA030199NCI NIH HHS R01 CA247500NCI NIH HHS R35 CA210043NCI NIH HHS U24 CA270823NCRR NIH HHS S10 RR027366NIH HHS S10 OD016262
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CD8-Positive T-LymphocytesProteasome Endopeptidase ComplexAcetylglucosamineAnimalsCell SurvivalMiceMitochondriaN-AcetylglucosaminyltransferasesProteomicsTOR Serine-Threonine KinasesAcetylglucosamineN-AcetylglucosaminyltransferasesO-GlcNAc transferaseProteasome Endopeptidase ComplexTOR Serine-Threonine Kinasesgenome-wide CRISPR/Cas9 screenmitochondrionmTOROGTproteasome

Identifiers

PMID36626549
PMCPMC9934350
OpenAlexW4315436879

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.